Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel
NASDAQ:CELU

Celularity Q4 2024 Earnings Report

Celularity logo
$0.77 -0.11 (-12.49%)
Closing price 05/11/2026 04:00 PM Eastern
Extended Trading
$0.80 +0.03 (+3.38%)
As of 08:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Celularity EPS Results

Actual EPS
-$0.59
Consensus EPS
-$1.50
Beat/Miss
Beat by +$0.91
One Year Ago EPS
N/A

Celularity Revenue Results

Actual Revenue
$18.13 million
Expected Revenue
$5.20 million
Beat/Miss
Beat by +$12.93 million
YoY Revenue Growth
N/A

Celularity Announcement Details

Quarter
Q4 2024
Date
5/8/2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Celularity's Q4 2024 Press ReleasePress Release
(8-K)
Celularity's Q4 2024 Annual reportAnnual report
(10-K)

Celularity Earnings Headlines

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
May 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nexgel-appoints-brian-kieser-and-kevin-harris-from-new-strategic-partner-sequence-lifescience-to-board-of-directors-1036113343
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
May 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/01/3286224/0/en/celularity-announces-filing-of-form-10-k-regains-nasdaq-compliance-and-highlights-continued-strategic-transformation.html
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 12 at 1:00 AM  |  American Alternative (Ad)
Inside the deal: After investor bails, Nexgel scrambles to save acquisition that will triple revenue
April 28, 2026  |  bizjournals.comhttps://www.bizjournals.com/philadelphia/news/2026/04/26/nexgel-langhorne-celularity-biomaterials-health.html
Langhorne’s Nexgel transforms near disaster into ‘three-team trade’ acquisition
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/langhorne-s-nexgel-transforms-near-disaster-into-three-team-trade-acquisition/ar-AA21UIz1
NEXGEL Appoints Ian Blackman as Chief Financial Officer
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3281691/0/en/nexgel-appoints-ian-blackman-as-chief-financial-officer.html
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells. Among its lead investigational candidates is a placental-derived NK cell therapy being evaluated in both oncology and immuno-infectious disease settings. Celularity also explores exosome-based approaches to deliver therapeutic proteins and RNA payloads to specific tissues.

Founded by Dr. Robert L. Hariri—who previously established and led Celgene’s cellular therapeutic research efforts—Celularity went public in April 2021 via a special purpose acquisition company (SPAC) transaction and now trades on the Nasdaq under the symbol CELU. The company is headquartered in Florham Park, New Jersey, with research and manufacturing operations designed to support scalable production of its cell therapy candidates.

Under the leadership of President and Chief Executive Officer Robert L. Hariri, M.D., Ph.D., Celularity brings together a team of experts in cell biology, process development and clinical research. The company maintains collaborations with academic centers and industry partners to advance its portfolio through clinical trials, with the goal of delivering novel, off-the-shelf therapies to patients worldwide.

View Celularity Profile
Earnings Tools